The novel treatment products in the treatment of haemophilia and other bleeding disorders have been a ‘hot topic’ of discussion already for several years. Many questions have been raised and many answers have been provided. 
However, it is only for a couple of years, or in some places even less, that one of these novel agents – bi-specific antibody – has been actually accessible to the patients with inhibitors. This has not been long enough time to build the sufficient volume of post marketing data, nor have all the questions answered. However, the experience among the patients and healthcare professionals is gradually accumulating and more and more answers can be provided.

The April edition of “Happy 1/2 Hour with an Expert in Haemophilia Care” – to take place on Wednesday, 22 April at 19:00 Brussels time – will focus on trying g to answer some of these questions around the bi-specific antibody in a session titled “Emicizumab. Practical aspects & implications.” We have invited once again a very knowledgeable and passionate speaker – Dr Maria Elisa Mancuso from Ospedale Maggiore Policlinico in Milan, Italy. 

This event will be a closed video conference. To join please register here.

Maria Elisa Mancuso (MD, PhD) is a senior consultant in Hematology with special interest in Haemostasis. She obtained a post-degree in Clinical and Experimental Hematology and a PhD in Clinical Methodology. She worked as a Clinical Assistant at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center in Milan (Italy) from 2008 to 2020. She is involved in clinical research and has published several original articles in peer-reviewed journals as Blood, Journal of Thrombosis and Haemostasis, Haematologica, Thrombosis and Haemostasis, British Journal of Haematology and Haemophilia. She is a member of several national and international scientific societies (AICE, SISET, ISTH, WFH, ASH, EAHAD). She is Co-Chair of the Scientific and Standardization Subcommittee of ISTH (SSC-ISTH) on FVIII, FIX and rare bleeding disorders. She has been involved as co-investigator in several clinical trials, and she takes care of both children and adults with hemophilia with a specific scientific interest in inhibitors, chronic hepatitis C, optimization of prophylaxis and novel therapies.

Your email address will not be published. Required fields are marked *